Affordable Access

Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.

Authors
Type
Published Article
Journal
Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
Publication Date
Volume
38
Issue
3
Pages
233–237
Identifiers
PMID: 17552391
Source
Medline

Abstract

The anatomic response to intravitreal bevacizumab injection in three patients with aggressive, posterior retinopathy of prematurity is described. In all cases, the worse eye was treated with a single intravitreal injection of 0.75 mg of bevacizumab as monotherapy or complementary to laser therapy. In 24 hours, all injected eyes showed regression of the tunica vasculosa lentis and iris vessel engorgement and disappearance of iris rigidity. In addition, plus disease and retinal proliferation began to regress. None of the eyes required additional treatment. Follow-up of up to 10 months

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F